Novo Nordisk has a two-tier board structure consisting of a Board of Directors and the Executive Management.
The two bodies are separate, and no one serves as a member of both.
The Board of Directors is responsible for the overall management of Novo Nordisk.
On behalf of shareholders, the Board of Directors actively contributes to developing the company and supervises Executive Management in its decisions and operations. The board of directors focuses on those activities that seek to effectively promote shareholders' interests and in such a way that the company achieves its objectives. The board's governance policies regulate its relationship with shareholders, the conduct of board affairs and the board's relationship with the executive management.
It consists of the president and CEO, and five other executives. Its responsibilities include organisation of the company and allocation of resources, strategies and policies, setting direction and ensuring timely information to the board and the stakeholders of Novo Nordisk.
Executive Committees
The Executive Management has established a number of executive committees to assist or implement Executive Management's decisions.
These include:
The Development Portfolio Committee overseeing, prioritising, and resourcing Development projects from an overall portfolio perspective
The Environment & Bioethics Committee identifying, developing and managing environmental and bioethical issues and strategies
The Disclosure Committees supervising the reliability of Novo Nordisk’s reporting
The Health Policy Committee identifying, developing and driving strategies and monitoring of performance in rel ation to global health issues
The Working Environment Council, which is the supreme health and safety authority for Novo Nordisk in Denmark (covering 56% of the workforce), whose members are representatives of management and employees. It plans, manages and coordinates the occupational health and safety work.
The European Works Council, whose members are representatives of employees in the affiliates in the EU countries (and Norway) and corporate management.
This page has been assessed by PricewaterhouseCoopers as part of its assessment of Novo Nordisk’s statement that it reports ‘in accordance’ with GRI. Please refer to Audit and assurance for a full description of the nature of assurance offered.
